Delirium is a state of confusion and altered level of consciousness characterized by a decline in cognitive function (Inouye, Westendorp, & Saczynski, 2014) . It comes on suddenly, usually following an acute stressor and may last for hours or even weeks before resolving. Common precipitating causes of delirium include surgery, sepsis, medications with strong anticholinergic effects, and immobility associated with physical restraint. Delirium has been known for centuries, but complete understanding of its presentations, causes, and treatment still elude clinicians who struggle to respond effectively to this enigmatic condition. Older adults with dementia are at greatest risk for delirium: 89% experience delirium when hospitalized, and between 24% and 76% die within one year of the index episode (Davis et al., 2012; Fick, Agostini, & Inouye, 2002) . In the first nationwide multicenter point prevalence study of delirium, Bellelli and colleagues (2016) reported that 22.9% of patients in acute and rehabilitation wards in Italy had delirium. Patients with dementia comprised the majority of those with delirium (52.9%), but only a small percentage of those without delirium (15.4%). Despite carrying the highest burden of delirium, there is inequitable representation in scientific investigations and a paucity of literature on delirium that occurs in people living with dementiacommonly termed delirium superimposed on dementia (DSD).
In the past two decades, delirium has received increased international attention because its devastating outcomes on the health of older adults and their caregivers are becoming better known. Older adults who experience a delirium episode have substantially higher mortality rates, longer hospital stays, further cognitive decline, and greater healthcare costs in comparison to those who do not experience delirium (Fick et al., 2002; Leslie, Marcantonio, Zhang, Leo-Summers, & Inouye, 2008; Morandi et al., 2014) . Family members who witness delirium also experience significant distress. Solutions to delirium require innovative thinking and strong advocacy. In 2015, iDelirium (www.idelirium.org), an international consortium of three delirium societies (Australasia Delirium Association, American Delirium Society, and European Delirium Association), was formed to provide a unified voice for advocating and advancing delirium care. The iDelirium consortium seeks to (1) increase international awareness of delirium;
(2) determine the global impact of delirium; (3) speak with one unified voice; and (4) share a common research agenda with outcome standardization. The purpose of this editorial, written on behalf of the members of iDelirium, is to describe the complexities in the recognition, diagnosis, and treatment of DSD, and to propose research that will meet those challenges.
DSD is challenging to recognize. At the bedside, clinicians often attribute 'confusion' to 'normal aging' or 'dementia' and consequently do not act upon it as the medical emergency it actually is (Inouye, Foreman, Mion, Katz, & Cooney, 2001) . Screening tools for delirium exist, but many require knowledge of the patient's baseline cognitive performance, which is especially challenging in acute care settings where the patient is not known. Other tools are considered too lengthy by staff to make them feasible for use on busy units. A recent national survey conducted by the American Nurses Association found that the majority of nursing staff indicated a need for instruments to help them identify delirium in high-risk patients (Assi, 2016) . Fick and her colleagues (2015) have developed an ultra-brief two-item screening instrument that has shown a sensitivity of 93% and specificity of 64%.Voyer and colleagues' RADAR, a screening tool that can be folded into routine bedside activities, has been tested in a variety of acute and long-term care settings with reported high staff satisfaction (Voyer et al., 2015) . In the community, the Family Confusion Assessment Method has shown to be a promising instrument for the detection of delirium when used by family caregivers (Steis et al., 2012) . Despite significant progress, there remains a critical need to prospectively validate screening instruments such as these in older adults with dementia. The identification of implementation frameworks that facilitate practice change by using a system-wide approach for improving recognition of DSD is equally important in future research efforts.
The diagnosis of DSD is complicated by the fact that its assessment is not addressed by the Diagnostic and Statistical Manual of Mental Disorders-5 or International Classification of Diseases-10, which are considered the standard criteria for delirium (Morandi et al., in press ). Beyond the difficulty in recognizing delirium in patients with dementia, there are significant challenges when conducting and interpreting neuropsychological assessments that are needed for a definitive DSD diagnosis. For example, inattention is considered a core feature of delirium, but attentional impairments have been noted in early stages of Alzheimer's disease and these impairments become more compromised and varied as the dementia progresses (Perry & Hodges, 1999) . The type of dementia is also a factor in the diagnosis of DSD. Patients with Lewy Body dementia, for example, have considerably greater impairment of attention compared to other dementias (Calderon et al., 2001) . There are data to indicate that a worsening of motor function, which is generally preserved in dementia, may be indicative of delirium in people with dementia and a better indicator than worsening of cognition, which is already affected by the neurodegenerative process (Bellelli et al., 2011) . Similarly, level of arousal may also be a better indicator of delirium than inattention, especially in later stages of dementia. Morandi and colleagues (in press) propose a research agenda that will advance our ability to diagnose DSD and differentiate it from dementia. They identify a critical need for research that addresses what type of attention (i.e. sustained, divided, and selected attention) should be tested by type of and severity of dementia, and what other essential tests support an accurate diagnosis of DSD (i.e. assessment of motor fluctuation and arousal).
Safe and effective pharmacological treatment of delirium is not established as the underlying disease mechanisms are still being actively sought, although inflammation, neurotransmitters, and genetic factors are some that have been proposed (Inouye et al., 2014) . Current published guidelines recommend a non-pharmacological approach as first-line delirium treatment (National Institute for Health and Clinical Excellence, 2010). These guidelines are mostly bereft of specific recommendations for people with dementia. As such, current practice is largely directed toward symptom management using antipsychotic or sedative medications (Inouye et al., 2014) . These medications carry an increased risk for mortality and other adverse outcomes in patients with dementia (Ballard, Waite, & Birks, 2006) ; there is little evidence to support their efficacy (Neufeld, Yue, Robinson, Inouye, & Needham, 2016) ; and they may actually prolong the duration of delirium (American Geriatrics Society Expert Panel, 2015) .
Multicomponent non-pharmacological interventions that modify delirium risk factors have been demonstrated to be efficacious for delirium prevention (Hshieh et al., 2015) . These interventions are directed at the multiple risk factors for delirium and include early ambulation, frequent orientation to surroundings, consistent use of hearing aids and glasses, cognitive stimulation, and optimal nutrition and hydration. Unfortunately, the evidence for their efficacy in treatment is lacking (Abraha et al., 2015) . One issue is that individual components within a multicomponent 'bundled' intervention confound one another, making it difficult to determine which component(s) might be most effective for an individual episode of delirium, as each episode is likely to have a unique set of contributors. Another issue is that aging and stage of dementia account for a great amount of variability in treatment response. Answers to questions about which components are more effective for some individuals than for others are essential for advancing the science of DSD. A new methodological framework called the multiphase optimization strategy (MOST) may have value here (Collins, Kugler, & Gwadz, 2016) . In MOST designs, the intervention may start with an initial single-component treatment, such as early ambulation, but then at a designated decision point, transition to an augmented treatment for non-responders to the initial treatment. The emphasis in this approach is on optimization. An initial step in the process is to identify singlecomponent candidate interventions for MOST trials. We have recently completed a trial of cognitively stimulating activities for resolution of DSD in post-acute care settings (Kolanowski et al., in press) . While delirium duration and severity did not improve under intervention, executive function and length of stay did. The most efficacious non-pharmacological components and their optimal dosage for impacting important DSD outcomes will depend on the etiology of each individual delirium episode and the relevant clinical characteristics of the patient. How these factors interact and respond to intervention remain major gaps in our knowledge.
Dementia complicates delirium outcomes. The effects of DSD continue long after the index episode and contribute to a more rapid trajectory of cognitive and functional decline (Fong et al., 2012) . Symptoms of delirium are more likely to persist in people with dementia and manifest as sub-syndromal delirium for months (Cole et al., 2015) . Cole and McCusker (2016) recently suggested that, for some older adults, delirium may become a chronic cognitive disorder, characterized by persistent symptoms punctuated with periods of acute exacerbation, much like the course of chronic heart failure. Given this evidence, future clinical trials will require extended follow-up to evaluate any long-term effects of interventions for DSD.
Finally, we have not yet prioritized the outcomes that matter most to patients and family in delirium interventional research. The Core Outcome Measures in Effectiveness Trials [COMET] group (http://www.comet-initiative.org/studies/ details/796) aims to reach international consensus on a core set of clinical trial outcomes considered most relevant for clinicians and patients with delirium. This work will improve the replicability and relevance of future DSD research, and these core measures should be incorporated in all future clinical trials.
People with dementia are at highest risk for delirium and the poor health and cost outcomes that occur following an episode. Around the globe there are positive steps being taken to improve the care and outcomes for these individuals. While guidelines for the treatment of delirium should continue to be instituted in the clinical area, there is a tremendous need for a coordinated international research agenda that will improve the recognition, diagnosis, and treatment of DSD.
